Sponsored by
This is a blog post from the chairman of the company that makes Val-083. I think this trial will accrue patients faster than they predict as the early results are impressive and there really are not many competing trials looking for this patient population: Patients with GBM who have failed Avastin and have unmethylated MGMT. Worth looking at this trial.